Mah M P, Aeberhard E E, Gilliam M B, Sherman M P
Department of Pediatrics, School of Medicine, University of California, Los Angeles.
Crit Care Med. 1993 May;21(5):712-20. doi: 10.1097/00003246-199305000-00015.
Pentoxifylline was evaluated for its ability to enhance inactivation of group B streptococci in lungs of prematurely born rabbits. Mechanisms associated with intrapulmonary streptococcal clearance and the pharmacodynamics of pentoxifylline were also investigated.
Randomized, controlled animal trial.
University research laboratory.
A total of 123 New Zealand rabbits were delivered prematurely by cesarean section and were used for clearance studies. Twenty-three preterm pups were additionally utilized to study the pharmacodynamics of pentoxifylline.
Preterm rabbits were infected with group B streptococcal aerosols and given intraperitoneal injections of either pentoxifylline (25, 12.5, and 12.5 mg/kg) or placebo at 0, 6, and 12 hrs after infection.
At 0, 4, and 24 hrs, the numbers of streptococci were determined in the left lung, while the right lung underwent bronchoalveolar lavage to quantify intra-alveolar leukocytes, phagocytosis of inhaled bacteria, and concentrations of lysozyme and tumor necrosis factor. In a separate experiment, blood and bronchoalveolar fluid from infected animals were analyzed for pentoxifylline content. Streptococcal proliferation was less in pentoxifylline-treated animals than in controls at 24 hrs (p < .01). Pulmonary macrophages and polymorphonuclear leukocytes recovered from bronchoalveolar lavage fluid did not differ in numbers or phagocytic activity. Pentoxifylline-treated animals had lower levels of lysozyme (p < .02) and tumor necrosis factor (p < .005) in bronchoalveolar lavage fluid compared with placebo-treated pups. Therapeutic levels of pentoxifylline were achieved in blood and bronchoalveolar lavage fluid.
Despite lowering lysozyme and tumor necrosis factor content in epithelial lining fluid, pentoxifylline improves the inactivation of group B streptococci in preterm rabbit lungs. These findings suggest that increased group B streptococcal clearance was coincident with an anti-inflammatory effect due to pentoxifylline. We conclude pentoxifylline may be clinically useful as an adjunctive therapy for group B streptococcal pneumonia in newborns.
评估己酮可可碱增强早产兔肺部B族链球菌灭活的能力。还研究了与肺内链球菌清除相关的机制以及己酮可可碱的药效学。
随机对照动物试验。
大学研究实验室。
总共123只新西兰兔通过剖宫产早产,并用于清除研究。另外23只早产幼崽用于研究己酮可可碱的药效学。
早产兔感染B族链球菌气溶胶,并在感染后0、6和12小时腹腔注射己酮可可碱(25、12.5和12.5mg/kg)或安慰剂。
在0、4和24小时,测定左肺中的链球菌数量,同时对右肺进行支气管肺泡灌洗,以量化肺泡内白细胞、吸入细菌的吞噬作用以及溶菌酶和肿瘤坏死因子的浓度。在另一个实验中,分析感染动物的血液和支气管肺泡灌洗液中的己酮可可碱含量。在24小时时,己酮可可碱治疗组动物的链球菌增殖低于对照组(p<0.01)。从支气管肺泡灌洗液中回收的肺巨噬细胞和多形核白细胞在数量或吞噬活性上没有差异。与安慰剂治疗的幼崽相比,己酮可可碱治疗组动物的支气管肺泡灌洗液中溶菌酶水平(p<0.02)和肿瘤坏死因子水平(p<0.005)较低。血液和支气管肺泡灌洗液中达到了己酮可可碱的治疗水平。
尽管己酮可可碱降低了上皮衬液中的溶菌酶和肿瘤坏死因子含量,但它改善了早产兔肺中B族链球菌的灭活。这些发现表明,B族链球菌清除增加与己酮可可碱的抗炎作用一致。我们得出结论,己酮可可碱作为新生儿B族链球菌肺炎的辅助治疗可能具有临床应用价值。